期刊文献+

顶空气相色谱法测定TM-2中溶剂残留量 被引量:8

Determination of residual solvents in TM-2 by headspace gas chromatography
原文传递
导出
摘要 目的建立TM-2中9种有机溶剂残留量测定法。方法采用气相色谱法,色谱柱为DB-624(30 m×530μm,3μm)毛细管柱,程序升温,检测器为FID,载气为氮气;采用顶空进样法,平衡温度为115℃,平衡时间为20 min。结果甲醇、乙腈、二氯甲烷、叔丁醇、正己烷、乙酸乙酯、四氢呋喃、三乙胺及吡啶线性关系良好(r≥0.992 9),平均回收率为89.9%--102.4%(RSD=3.6%),检测限分别为0.28、0.30、0.53、0.22、0.03、0.07、0.05、0.15、0.15 mg·L-1。结论本方法可用于TM-2原料药中残留溶剂的检查。 Objective To develop a method for determination of nine kinds of residual solvents in TM-2 by headspace gas chromatography. Methods The residual solvents were separated on DB-624( 30 m × 530 μm,3 μm) capillary chromatography column using temperature programming. Nitrogen gas was used as carrier gas with FID as detector. Results There were good linear relationships in the experimental concentrations of methanol,acetonitrile,dichloromethane,tert-butylalcohol,n-hexane,ethyl acetate,tetrahydrofuran,triethylamine,pyridine( r ≥ 0. 992 9). The average recoveries were ranged from 89. 9% to 102. 4%( RSD =3. 6%). The limit of detection were 0. 28,0. 30,0. 53,0. 22,0. 03,0. 07,0. 05,0. 15 and 0. 15 mg·L- 1,respectively. Conclusions The method is simple,sensitive and accurate. It could be used for detection of residual solvents in TM-2.
出处 《沈阳药科大学学报》 CAS CSCD 北大核心 2015年第7期523-526,536,共5页 Journal of Shenyang Pharmaceutical University
关键词 TM-2 顶空气相色谱法 残留溶剂 TM-2 gas chromatography residual solvent
  • 相关文献

参考文献4

  • 1张万年,缪震元.抗肿瘤创新药物研究进展[J].中国新药杂志,2010,19(24):2277-2284. 被引量:13
  • 2于跃,王军飞,王长云,李英霞.抗多药耐药紫杉烷类抗肿瘤药物研究进展[J].中国现代应用药学,2012,29(1):16-23. 被引量:8
  • 3SHI Jian-li, CHEN Xi, GU Yue-chen, et al. Preformula- tion and development of chemically stable lipid emul- sions containing a novel taxane derivative, TM-2 [ J 1. Eur J Lipid Sci Techno1,2014 ,116 :486 - 496.
  • 4李英霞,耿美玉,王军飞,等.抗多药耐药紫杉烷类衍生物及其制备方法和应用:中国,CNl02241648A[P].2011—11—16.

二级参考文献103

  • 1GUTIERREZ ME, KUMMAR S, GIACCONE G. Next generation oncology drug development: opportunities and challenges [J]. Nat Rev Clin Oncol,2009,6 (5) :259 - 265.
  • 2CASSIDY J,TWELVES C,CUTSEM EV,et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin [ J ]. Ann Oncol,2002,13 (4) :566 - 575.
  • 3KAMINSKAS E, FARRELL A, ABRAHAM S, et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes[J]. Clin Cancer Res,2005 ,11(10) :3604 - 3608.
  • 4BONATE P,ARTHAUD L,CANTRELL WR,et al. Discovery and development of clofarabine: a nucleoside analogue for treating cancer[J]. Nat Rev Drug Discov,2006,5 (10) :855 -863.
  • 5COHEN M,JOHNSON J,MASSIE T,et al. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/ lymphoma[ J]. Clin Cancer Res ,2006,12 ( 15 ) :5329 - 5335.
  • 6KANTARJIAN H, O'BRIEN S, HUANG XL, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome[J]. Cancer,2007,109 (6) :1133 - 1137,.
  • 7DUMONTET C,JORDAN MA,LEE FFY,et al. Ixabepilone: targeting βIII-tubulin expression in taxanc-resistant malignancies [ J ]. Mol Cancer Ther,2009,8 ( 1 ) : 17 - 25.
  • 8CIGLER T,VAHDAT LT. Eribulin mesylate for the treatment of breast cancer[ J]. Expert Opin Pharmacol,2010, 11 (9) : 1587 - 1593.
  • 9HUSSAR D,DANIEL WL. New drugs: sipuleucel-T, cabazitaxel, and collagenase clostridium histolyticum [ J ]. J Am Pharm Assoc,2010,50(6) :772 -775.
  • 10SAVAGE DG, ANTMAN KH. Imatinib mesylate: a new oral targeted therapy[J]. N Eng J Med,2002,346(6):683-693.

共引文献19

同被引文献52

引证文献8

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部